Resilience Stock

resilience.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $2.03B

Resilience is a biomanufacturing business focusing on pharmaceuticals. Their team is focused on producing complex solutions such as gene therapies, vaccines, and cell therapies. Resilience was founded in 2020 by Drew Oetting, Patrick Yang Ph.D, Sandesh Mahatme, and Rahul Singhvi Ph.D and is headquartered in La Jolla, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Resilience, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Resilience’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Resilience.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Resilience investors also invested in these private companies

Dragoeer Investment Group
Mubadala Investment Company
R-Squared Ventures
Global Health Investment Fund

Team

Management Team

Syed Husain
Chief Commercial Officer
Elliot Menschik Ph.D
Chief Digital Officer
Spencer Fisk
Chief Technology Officer
Ori Solomon JD
Chief Legal Officer, General Counsel
Duane Avant
Chief Quality Officer
Viet Nguyen
Chief Manufacturing Officer
Rahul Singhvi Ph.D
Co-Founder, Chief Executive Officer & Board Member
Sandesh Mahatme
Co-Founder, President, Chief Financial Officer & Chief Operating Officer
Drew Oetting
Co-Founder & Board Member
Patrick Yang
Co-Founder

Board Members

Scott Gottlieb MD
New Enterprise Associates
Susan Desmond-Hellmann MD
GV

Frequently Asked Questions About Resilience’s Stock

plusminus
Can you buy Resilience’s stock?
Resilience is not publicly traded on NYSE or NASDAQ in the U.S. To buy Resilience’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Resilience’s stock?
Yes, you can sell stock of a private company like Resilience. Forge can help you sell your Resilience stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Resilience’s stock price?
Resilience is a privately held company and therefore does not have a public stock price. However, you may access Resilience’s private market stock price with Forge Data.
plusminus
What is Resilience’s stock ticker symbol?
Resilience does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

On the defense: Resilience bags $410m US Gov contract
The $410 million long-term funding agreement with the US Department of Defense (DoD), in collaboration with the US International Development Finance Corporation (DFC), aims to support Resilience’s capabilities and strengthen domestic bioproduction.
As US plots biomanufacturing boost, National Resilience nets $410M loan from Defense Department
Amid a spate of drug production pledges from the White House, U.S.-based manufacturer National Resilience has scored new government financing to keep its mission running for the long haul.
AstraZeneca to sell Ohio site to biotech firm Resilience
AstraZeneca is selling its West Chester manufacturing site in Ohio in the United States to biomanufacturing company National Resilience Inc, the company said on Tuesday.
Updated on: Apr 19, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.